Chemed Corporation $CHE Shares Acquired by UBS Group AG

Key Points

• UBS Group AG increased its Chemed position by 8.4% in Q4, buying 9,364 shares to hold 121,482 shares (about 0.86% of the company) worth approximately $51.98 million.
• CEO Kevin J. Mcnamara sold 2,000 shares on May 1 at an average $421.13 for $842,260, reducing his stake to 90,219 shares; institutional investors own about 95.85% of the stock and insiders own 3.33%.
• Chemed beat EPS estimates ($5.65 vs. $5.30) but slightly missed revenue, set FY2026 guidance of $24.00–$24.75 EPS, and carries a Wall Street consensus rating of Hold with a $501.50 target.

UBS Group AG grew its position in Chemed Corporation (NYSE:CHE - Free Report) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 121,482 shares of the company's stock after purchasing an additional 9,364 shares during the period. UBS Group AG owned approximately 0.86% of Chemed worth $51,977,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in shares of Chemed by 71.4% in the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company's stock valued at $27,000 after purchasing an additional 25 shares during the period. First Horizon Corp acquired a new stake in Chemed during the 3rd quarter worth about $31,000. Geneos Wealth Management Inc. grew its position in Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock worth $61,000 after purchasing an additional 76 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new stake in Chemed during the 3rd quarter worth about $45,000. Finally, Employees Retirement System of Texas acquired a new stake in Chemed during the 3rd quarter worth about $64,000. 95.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Oppenheimer cut their price target on Chemed from $580.00 to $500.00 and set an "outperform" rating on the stock in a research report on Friday, February 27th. Zacks Research raised Chemed from a "strong sell" rating to a "hold" rating in a research report on Monday, April 27th. Royal Bank Of Canada increased their price target on Chemed from $422.00 to $436.00 and gave the stock a "sector perform" rating in a research report on Monday, April 27th. Jefferies Financial Group lowered shares of Chemed from a "buy" rating to a "hold" rating in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research report on Saturday. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Chemed currently has a consensus rating of "Hold" and a consensus target price of $501.50.

Insider Activity

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at $37,993,927.47. The trade was a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.33% of the stock is owned by corporate insiders.

Chemed Price Performance

Chemed stock opened at $427.85 on Wednesday. The company's fifty day moving average price is $398.34 and its 200 day moving average price is $425.88. Chemed Corporation has a 1 year low of $365.20 and a 1 year high of $583.96. The stock has a market capitalization of $5.68 billion, a P/E ratio of 23.32, a P/E/G ratio of 1.60 and a beta of 0.54. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85.

Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.30 by $0.35. The firm had revenue of $657.51 million for the quarter, compared to analysts' expectations of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.63 EPS. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities research analysts anticipate that Chemed Corporation will post 22.3 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 13th. Stockholders of record on Monday, February 23rd were paid a $0.60 dividend. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. Chemed's payout ratio is currently 13.08%.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.